• Je něco špatně v tomto záznamu ?

Single-dose cefixime 800 mg plus doxycycline 100 mg twice a day for 7 days compared with single-dose ceftriaxone 1 g plus single-dose azithromycin 2 g for treatment of urogenital, rectal, and pharyngeal gonorrhoea: a randomised clinical trial

B. Bížová, P. Procházka, E. Nyčová, P. Bořil, J. Kubele, A. Poláková, Z. Zemanová, M. Unemo, F. Rob

. 2024 ; 30 (2) : 211-215. [pub] 20231118

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu hodnocení ekvivalence, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007405

OBJECTIVES: To evaluate the efficacy and tolerability of a single dose of oral cefixime 800 mg plus oral doxycycline 100 mg twice a day for 7 days, compared with a recommended single dose of ceftriaxone plus single dose of oral azithromycin, for treatment of uncomplicated urogenital, rectal, or pharyngeal gonorrhoea. METHODS: A noninferiority, open-label, multicentre randomized controlled trial was conducted in Prague, Czech Republic. Some 161 patients, 18-65 years of age diagnosed with uncomplicated urogenital, rectal, or pharyngeal gonorrhoea by nucleic acid amplification test (NAAT) were randomized to treatment with single dose of cefixime 800 mg plus doxycycline 100 mg twice a day for 1 week or a single dose of ceftriaxone 1 g intramuscularly plus single dose of azithromycin 2 g. The primary outcome was the number of participants with negative culture and NAAT at 1 week and 3 weeks, respectively, after treatment initiation. RESULTS: In all, 161 patients were randomized and 152 were included in per-protocol analyses. All 76 (100%; 95% CI, 0.95-1.00) patients treated with ceftriaxone plus azithromycin achieved negative cultures and NAAT after treatment. In the cefixime plus doxycycline arm at week 1, culture was negative in all 76 (100%) patients; at week 3, culture was negative in 70 of the 76 patients (92%; 95% CI, 0.84-0.97) and NAAT negative in 66 of the 76 patients (87%; 95% CI, 0.77-0.94). At week 3, culture and NAAT were negative in 65 of the 76 patients (86%; 95% CI, 0.76-0.93). Per-protocol risk difference was 14.5%; 95% CI, 6.56-22.38. All treatment failures observed in the cefixime arm were pharyngeal gonorrhoea cases. DISCUSSION: The combination of cefixime and doxycycline did not achieve noninferiority to ceftriaxone and azithromycin for treatment of gonorrhoea when including pharyngeal gonorrhoea. It did, however, show high efficacy for urogenital and rectal gonorrhoea.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007405
003      
CZ-PrNML
005      
20240423155927.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cmi.2023.11.006 $2 doi
035    __
$a (PubMed)37981059
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bížová, Beatrice $u Dermatovenereology Department, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic
245    10
$a Single-dose cefixime 800 mg plus doxycycline 100 mg twice a day for 7 days compared with single-dose ceftriaxone 1 g plus single-dose azithromycin 2 g for treatment of urogenital, rectal, and pharyngeal gonorrhoea: a randomised clinical trial / $c B. Bížová, P. Procházka, E. Nyčová, P. Bořil, J. Kubele, A. Poláková, Z. Zemanová, M. Unemo, F. Rob
520    9_
$a OBJECTIVES: To evaluate the efficacy and tolerability of a single dose of oral cefixime 800 mg plus oral doxycycline 100 mg twice a day for 7 days, compared with a recommended single dose of ceftriaxone plus single dose of oral azithromycin, for treatment of uncomplicated urogenital, rectal, or pharyngeal gonorrhoea. METHODS: A noninferiority, open-label, multicentre randomized controlled trial was conducted in Prague, Czech Republic. Some 161 patients, 18-65 years of age diagnosed with uncomplicated urogenital, rectal, or pharyngeal gonorrhoea by nucleic acid amplification test (NAAT) were randomized to treatment with single dose of cefixime 800 mg plus doxycycline 100 mg twice a day for 1 week or a single dose of ceftriaxone 1 g intramuscularly plus single dose of azithromycin 2 g. The primary outcome was the number of participants with negative culture and NAAT at 1 week and 3 weeks, respectively, after treatment initiation. RESULTS: In all, 161 patients were randomized and 152 were included in per-protocol analyses. All 76 (100%; 95% CI, 0.95-1.00) patients treated with ceftriaxone plus azithromycin achieved negative cultures and NAAT after treatment. In the cefixime plus doxycycline arm at week 1, culture was negative in all 76 (100%) patients; at week 3, culture was negative in 70 of the 76 patients (92%; 95% CI, 0.84-0.97) and NAAT negative in 66 of the 76 patients (87%; 95% CI, 0.77-0.94). At week 3, culture and NAAT were negative in 65 of the 76 patients (86%; 95% CI, 0.76-0.93). Per-protocol risk difference was 14.5%; 95% CI, 6.56-22.38. All treatment failures observed in the cefixime arm were pharyngeal gonorrhoea cases. DISCUSSION: The combination of cefixime and doxycycline did not achieve noninferiority to ceftriaxone and azithromycin for treatment of gonorrhoea when including pharyngeal gonorrhoea. It did, however, show high efficacy for urogenital and rectal gonorrhoea.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mladý dospělý $7 D055815
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a azithromycin $x terapeutické užití $7 D017963
650    _2
$a cefixim $x terapeutické užití $7 D020682
650    12
$a ceftriaxon $7 D002443
650    _2
$a doxycyklin $x terapeutické užití $7 D004318
650    12
$a gonorea $x farmakoterapie $x mikrobiologie $7 D006069
650    _2
$a Neisseria gonorrhoeae $7 D009344
655    _2
$a hodnocení ekvivalence $7 D000073843
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Procházka, Přemysl $u Venereology Prague, Medicentrum Beroun, Prague, Czech Republic
700    1_
$a Nyčová, Elka $u Department of Microbiology, University Hospital Bulovka, Prague, Czech Republic
700    1_
$a Bořil, Petr $u Clinical Laboratory, Medicentrum Beroun, Beroun, Czech Republic
700    1_
$a Kubele, Jan $u Clinical Microbiology and ATB Centre, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Poláková, Anna $u Department of Microbiology, University Hospital Bulovka, Prague, Czech Republic
700    1_
$a Zemanová, Zuzana $u Clinical Microbiology and ATB Centre, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Unemo, Magnus $u World Health Organization Collaborating Centre for Gonorrhoea and Other STIs, Department of Laboratory Medicine, Microbiology, Faculty of Medicine of Health, Örebro University, Örebro, Sweden; Institute for Global Health, University College London, London, United Kingdom
700    1_
$a Rob, Filip $u Dermatovenereology Department, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic. Electronic address: filip.rob@bulovka.cz
773    0_
$w MED00001139 $t Clinical microbiology and infection $x 1469-0691 $g Roč. 30, č. 2 (2024), s. 211-215
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37981059 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155924 $b ABA008
999    __
$a ok $b bmc $g 2081400 $s 1217172
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 30 $c 2 $d 211-215 $e 20231118 $i 1469-0691 $m Clinical microbiology and infection $n Clin Microbiol Infect $x MED00001139
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace